Anti-adherent compositions and methods of inhibiting the adherence of microbes to a surface

ABSTRACT

Methods of inhibiting microbes from attaching to a surface and anti-adherent compositions are disclosed. One method can include providing an anti-adherent composition that includes an anti-adherent agent configured to inhibit microbes from attaching to the surface. The anti-adherent agent can be: Acrylates Copolymer, Trimethylpentanediol/Adipic Acid/Glycerin crosspolymer, Trimethylpentanediol/Adipic Acid Copolymer, Ethylhexyl Stearate, Ethylhexyl Salicylate, Acrylates/C12-22 Alkylmethacrylate Copolymer, Octocrylene, Ethylene Oxide/Propylene Oxide Block Copolymer, Polyquaternium-101, or any combinations thereof. The method can include applying the composition to the surface and allowing at least some of the composition to remain on the surface such that the anti-adherent agent inhibits microbes from attaching to the surface. The anti-adherent composition can include a humectant and can be non-antimicrobial.

TECHNICAL FIELD

Disclosed are compositions with anti-adherent properties and methods ofinhibiting the adherence of microbes to a surface. More specifically,disclosed are compositions that include an anti-adherent agent thatinhibits the adherence of microbes to a surface and methods of usingsuch compositions. The microbes may be at least one of DNA viruses, RNAviruses, Gram negative bacteria, or Gram positive bacteria. Thecomposition may be applied to or incorporated into articles such aswipes, or into ointments, lotions, creams, salves, aerosols, gels,suspensions, sprays, foams, washes, or the like.

BACKGROUND OF THE DISCLOSURE

Communicable human infections pass from person to person through variousmeans such as food, aerosols, surfaces and hands. For example, in theUnited States, foodborne pathogens alone cause an estimated 76 millioncases of illness, 325,000 hospitalizations and 5,000 deaths per year.This results in the spending or loss of several billion dollars due toabsenteeism, cost of medication, and hospitalization.

Foodborne pathogens are typically a result of poor cleaning of hands andsurfaces on which food is prepared. In fact, the kitchen is one of themost contaminated sites in the home. High fecal and coliformconcentrations can be found in sponges, dishcloths, and the kitchensink. Of course, there are other pathogens lurking elsewhere in thehome, at the office, and in public places such as public bathrooms,restaurants, malls, theaters, health-care facilities, etc. Suchpathogens include bacteria, protein, active enzymes, viruses, and manyother microbes that can lead to health problems.

DNA viruses, including the adenovirus, are among these pathogens thatcan be spread and lead to health problems, such as the common cold, sorethroats, pneumonia, and diarrhea. Other DNA viruses include herpesviruses, such as HSV-1, HSV-2, cytomegalovirus, and Epstein-Barr. OtherDNA viruses can lead to diseases such as smallpox and chickenpox. RNAviruses, including influenza, noroviruses, rhinoviruses, polio virus,and enteroviruses, are also common causes of diseases in humans. Theseviruses can lead to symptoms of vomiting, diarrhea, body aches, andfevers, among others. DNA and RNA viruses, like other pathogens, can becommonly spread by shaking hands with infected people or touching asurface or object with such viruses on it.

Gram negative bacteria can include Escherichia coli (E. coli) and otherGram negative rods (e.g., Entereobacteria, Salmonella choleraesuis,Klebsiella pneumoniae, Pseudomonas aeruginosa); Gram negative curvedrods (e.g., Vibrio, Heliobacter, Campylobacter, etc.); and Gram negativecocci (e.g., Neisseria). Gram negative bacteria can cause diarrhea,urinary tract infections, respiratory illnesses and pneumonia, and otherillnesses. Gram positive bacteria can include Staphylococcus aureus (S.aureus). Other Gram positive bacteria include Gram positive rods (e.g.,Bacillus, Clostridium, Listeria, etc.) and Gram positive cocci (e.g.,Staphylococcus, Streptococcus, etc.). Gram positive bacteria can causeskin infections, pneumonia, and meningitis, among other illnesses. Gramnegative and Gram positive bacteria can be commonly spread by shakinghands with infected people or by touching a surface or object with suchbacteria on it.

There are products used today that are used to clean skin and hardsurfaces where pathogens may be deposited, such as soaps, handsanitizers, sprays and wipes. However, even the most diligent efforts tokeep clean can be hindered by factors such as surface topography, thepresence of hair, and the like. These factors can cause pathogens tobetter adhere to a surface. Other limiting factors include skinsensitivity due to the handling of cleaning products or the applicationthereof.

There remains a need for methods of reducing the adherence of microbesto a surface as well as compositions for accomplishing the same. Theanti-adherent composition can be applied to surfaces or incorporatedinto articles, wherein the compositions inhibit the adherence ofmicrobes. Desirably, the compositions are skin friendly, cost effective,and convenient to use.

SUMMARY OF THE DISCLOSURE

In one aspect of the disclosure, a method of inhibiting microbes fromattaching to a surface can include providing an anti-adherentcomposition. The anti-adherent composition can include an anti-adherentagent configured to inhibit microbes from attaching to the surface. Theanti-adherent agent can be selected from the group consisting of:Acrylates Copolymer, Trimethylpentanediol/Adipic Acid/GlycerinCrosspolymer, Trimethylpentanediol/Adipic Acid copolymer, EthylhexylStearate, Ethylhexyl Salicylate, Acrylates/C12-22 AlkylmethacrylateCopolymer, Octocrylene, Ethylene Oxide/Propylene Oxide Block Copolymer,and Polyquaternium-101, and any combinations thereof. The method canfurther include applying the composition to the surface. The method canalso include allowing at least some of the composition to remain on thesurface such that the anti-adherent agent inhibits microbes fromattaching to the surface.

In another aspect of the disclosure, an anti-adherent composition forpreventing microbes from attaching to a surface can include ananti-adherent agent and a humectant. The anti-adherent agent can beselected from the group consisting of: Trimethylpentanediol/AdipicAcid/Glycerin Crosspolymer, Trimethylpentanediol/Adipic Acid copolymer,Ethylhexyl Stearate, and Acrylates/C12-22 Alkylmethacrylate Copolymer,and any combinations thereof.

In yet another aspect of the disclosure, an anti-adherent compositionfor preventing microbes from attaching to a surface can include ananti-adherent agent and a humectant. The anti-adherent agent can beselected from the group consisting of: Acrylates Copolymer,Trimethylpentanediol/Adipic Acid/Glycerin Crosspolymer,Trimethylpentanediol/Adipic Acid copolymer, Ethylhexyl Stearate,Ethylhexyl Salicylate, Acrylates/C12-22 Alkylmethacrylate Copolymer, andPolyquaternium-101, and any combinations thereof. The anti-adherentcomposition can be non-antimicrobial.

DETAILED DESCRIPTION OF THE DISLOSURE

The present disclosure is directed to a method of inhibiting theadherence of microbes to a surface and an anti-adherent compositioncontaining an anti-adherent agent and a carrier that inhibits theadherence of microbes to a surface. The composition can be applied to asurface in the form of a liquid, gel, or foam; or incorporated into awash. In addition, the composition can be applied to a surface with avehicle such as a wipe.

The anti-adherent composition may be used on biotic surfaces such asskin or plants; or abiotic surfaces such as food prep surfaces; hospitaland clinic surfaces; household surfaces; automotive, train, ship andaircraft surfaces; and the like; as long as the surface is compatiblewith the ingredients of the composition. Applying the anti-adherentcomposition to such surfaces can help prevent the amount or thelikelihood that microbes will adhere to those surfaces, thus, lesseningthe likelihood of further transferring of the microbes.

Importantly, preferred embodiments of the anti-adherent composition ofthe present disclosure are not antimicrobial (“non-antimicrobial”). Inother words, in preferred embodiments the anti-adherent composition doesnot include an effective amount of any antimicrobial agent(s). Forpurposes of this disclosure, an effective amount of an antimicrobialagent can be considered as such a concentration such that a kill of adesired microbe reaches the IC₅₀ (inhibitory concentration 50%) for thatdesired microbe with that antimicrobial agent. The IC₅₀ is defined asthe amount of antimicrobial agent that is able to reduce the populationof a selected microbe by 50% at a defined contact time and incubationtemperature. In some embodiments, the anti-adherent composition can befree of antimicrobial agents. In these preferred embodiments in whichthe anti-adherent composition is non-antimicrobial, the anti-adherentcomposition seeks to prevent attachment of microbes to a surface, noteradicate or inactivate the microbes. This distinction can provide abenefit for the effectiveness for preventing the further spreading ofmicrobes as concerns grow about the increasing microbial resistance tocommon antimicrobial treatments. However, in some alternativeembodiments, as will be discussed further below, it is contemplated thatthe anti-adherent composition can include antimicrobial agents at aneffective amount such that the anti-adherent composition isantimicrobial.

Anti-Adherent Agents

Anti-adherent agents suitable for use in the composition can inhibitmicrobes from attaching to a surface. Suitable anti-adherent agents caninclude Acrylates Copolymer, Trimethylpentanediol/Adipic Acid/GlycerinCrosspolymer, Trimethylpentanediol/Adipic Acid Copolymer, EthylhexylStearate, Ethylhexyl Salicylate, Acrylates/C12-22 AlkylmethacrylateCopolymer, Octocrylene, Ethylene Oxide/Propylene Oxide Block Copolymer,and Polyquaternium-101. The anti-adherent agents can benon-antimicrobial.

An exemplary Acrylates Copolymer can be Carbopol® Aqua SF-1 Polymeravailable from The Lubrizol Corporation. An exemplaryTrimethylpentanediol/Adipic Acid/Glycerin Crosspolymer can be Lexorez®200 available from Inolex. An exemplary Trimethylpentanediol/Adipic AcidCopolymer can be Lexorez® TL-8 available from Inolex. An exemplaryEthylhexyl Stearate can be Cetiol® 868 available from BASF Corporation.An exemplary Ethylhexyl Salicylate can be Escalol® 587 available fromAshland Inc. An exemplary Acrylates/C12-22 Alkylmethacrylate Copolymercan be Allianz OPT available from Ashland Inc. An exemplary Octocrylenecan be Escalol® 597 available from Ashland Inc. An exemplary EthyleneOxide/Propylene Oxide Block Copolymer can be Pluronic® 85 available fromBASF Corporation. An exemplary Polyquaternium-101 can be Deposilk Q1available from Air Products and Chemicals, Inc.

Some embodiments of the anti-adherent compositions of the presentdisclosure can be suitably made with an anti-adherent agent in an amountof from about 0.01% (by the total weight of the composition) to about20% (by total weight of the composition), or preferably from about 0.05%(by total weight of the composition) to about 15% (by total weight ofthe composition), or more preferably from about 0.1% (by total weight ofthe composition) to about 10% (by total weight of the composition). Insome preferred embodiments, the anti-adherent composition can include ananti-adherent agent in an amount from about 2.0% (by the total weight ofthe composition) to about 5.0% (by the total weight of the composition).However, it is contemplated that anti-adherent compositions of thepresent disclosure can be outside of these ranges. For example, in someembodiments, the anti-adherent composition can include an anti-adherentagent that provides 100% of the total weight of the anti-adherentcomposition.

Carriers

The anti-adherent compositions of the present disclosure may beformulated with one or more conventional and compatible carriermaterials. The anti-adherent composition may take a variety of formsincluding, without limitation, aqueous solutions, gels, balms, lotions,suspensions, creams, milks, salves, ointments, sprays, emulsions, oils,resins, foams, solid sticks, aerosols, and the like. Liquid carriermaterials suitable for use in the instant disclosure include thosewell-known for use in the cosmetic and medical arts as a basis forointments, lotions, creams, salves, aerosols, gels, suspensions, sprays,foams, washes, and the like, and may be used in their establishedlevels.

Non-limiting examples of suitable carrier materials include water,emollients, humectants, polyols, surfactants, esters, perfluorocarbons,silicones, and other pharmaceutically acceptable carrier materials. Inone embodiment, the carrier is volatile, allowing for immediatedeposition of the anti-adherent ingredient to the desired surface whileimproving overall usage experience of the product by reducing dryingtime. Non-limiting examples of these volatile carriers include 5 cstDimethicone, Cyclomethicone, Methyl Perfluoroisobutyl Ether, MethylPerfluorobutyl Ether, Ethyl Perfluoroisobutyl Ether and EthylPerfluorobutyl Ether. Unlike conventional volatile carriers such asethanol or isopropyl alcohol, these carriers have no antimicrobialeffect.

In one embodiment, the anti-adherent compositions can optionally includeone or more emollients, which typically act to soften, soothe, andotherwise lubricate and/or moisturize the skin. Suitable emollients thatcan be incorporated into the compositions include oils such as alkyldimethicones, alkyl methicones, alkyldimethicone copolyols, phenylsilicones, alkyl trimethylsilanes, dimethicone, dimethiconecrosspolymers, cyclomethicone, lanolin and its derivatives, fattyesters, glycerol esters and derivatives, propylene glycol esters andderivatives, alkoxylated carboxylic acids, alkoxylated alcohols, fattyalcohols, and combinations thereof.

Some embodiments of the anti-adherent compositions may include one ormore emollients in an amount of from about 0.01% (by total weight of thecomposition) to about 20% (by total weight of the composition), or fromabout 0.05% (by total weight of the composition) to about 10% (by totalweight of the composition), or from about 0.10% (by total weight of thecomposition) to about 5% (by total weight of the composition).

In another embodiment the anti-adherent compositions include one or moreesters. The esters may be selected from cetyl palmitate, stearylpalmitate, cetyl stearate, isopropyl laurate, isopropyl myristate,isopropyl palmitate, and combinations thereof. The fatty alcoholsinclude octyldodecanol, lauryl, myristyl, cetyl, stearyl, behenylalcohol, and combinations thereof. Ethers such as eucalyptol, ceterarylglucoside, dimethyl isosorbic polyglyceryl-3 cetyl ether, polyglyceryl-3decyltetradecanol, propylene glycol myristyl ether, and combinationsthereof can also suitably be used as emollients. Other suitable estercompounds for use in the anti-adherent compositions or the presentdisclosure are listed in the International Cosmetic IngredientDictionary and Handbook, 11th Edition, CTFA, (January, 2006) ISBN-10:1882621360, ISBN-13: 978-1882621361, and in the 2007 Cosmetic BenchReference, Allured Pub. Corporation (Jul. 15, 2007) ISBN-10: 1932633278,ISBN-13: 978-1932633276, both of which are incorporated by referenceherein to the extent they are consistent herewith.

Humectants that are suitable as carriers in the anti-adherentcompositions of the present disclosure include, for example, glycerin,glycerin derivatives, hyaluronic acid, hyaluronic acid derivatives,betaine, betaine derivatives amino acids, amino acid derivatives,glycosaminoglycans, glycols, polyols, sugars, sugar alcohols,hydrogenated starch hydrolysates, hydroxy acids, hydroxy acidderivatives, salts of PCA and the like, and combinations thereof.Specific examples of suitable humectants include honey, sorbitol,hyaluronic acid, sodium hyaluronate, betaine, lactic acid, citric acid,sodium citrate, glycolic acid, sodium glycolate, sodium lactate, urea,propylene glycol, butylene glycol, pentylene glycol, ethoxydiglycol,methyl gluceth-10, methyl gluceth-20, polyethylene glycols (as listed inthe International Cosmetic Ingredient Dictionary and Handbook such asPEG-2 through PEG 10), propanediol, xylitol, maltitol, or combinationsthereof. Humectants are beneficial in that they prevent or reduce thechance that the anti-adherent film, formed after the anti-adherent agentis applied to a surface, will crack.

The anti-adherent compositions of the disclosure may include one or morehumectants in an amount of about 0.01% (by total weight of thecomposition) to about 20% (by total weight of the composition), or about0.05% (by total weight of the composition) to about 10% by total weightof the composition), or about 0.1% (by total weight of the composition)to about 5.0% (by total weight of the composition).

The anti-adherent compositions may include water. For instance, wherethe anti-adherent composition is a wetting composition, such asdescribed below for use with a wet wipe, the composition will typicallyinclude water. The anti-adherent compositions can suitably comprisewater in an amount of from about 0.01% (by total weight of thecomposition) to about 99.98% (by total weight of the composition), orfrom about 1.00% (by total weight of the composition) to about 99.98%(by total weight of the composition), or from about 50.00% (by totalweight of the composition) to about 99.98% (by total weight of thecomposition), or from about 75.00% (by total weight of the composition)to about 99.98% (by total weight of the composition).

In an embodiment where the anti-adherent composition serves as a wash(e.g. shampoo; surface cleaner; or hand, face, or body wash), theanti-adherent composition will include one or more surfactants. Thesemay be selected from anionic, cationic, nonionic, zwitterionic, andamphoteric surfactants. Amounts may range from 0.1 to 30%, or from 1 to20%, or from 3 to 15% by total weight of the composition.

Suitable anionic surfactants include, but are not limited to, C₈ to C₂₂alkane sulfates, ether sulfates and sulfonates. Among the suitablesulfonates are primary C₈ to C₂₂ alkane sulfonate, primary C₈ to C₂₂alkane disulfonate, C₈ to C₂₂ alkene sulfonate, C₈ to C₂₂ hydroxyalkanesulfonate or alkyl glyceryl ether sulfonate. Specific examples ofanionic surfactants include ammonium lauryl sulfate, ammonium laurethsulfate, triethylamine lauryl sulfate, triethylamine laureth sulfate,triethanolamine lauryl sulfate, triethanolamine laureth sulfate,monoethanolamine lauryl sulfate, monoethanolamine laureth sulfate,diethanolamine lauryl sulfate, diethanolamine laureth sulfate, lauricmonoglyceride sodium sulfate, sodium lauryl sulfate, sodium laurethsulfate, potassium laureth sulfate, sodium lauryl sarcosinate, sodiumlauroyl sarcosinate, potassium lauryl sulfate, sodium trideceth sulfate,sodium methyl lauroyl taurate, sodium lauroyl isethionate, sodiumlaureth sulfosuccinate, sodium lauroyl sulfosuccinate, sodium tridecylbenzene sulfonate, sodium dodecyl benzene sulfonate, sodium laurylamphoacetate and mixtures thereof. Other anionic surfactants include theC₈ to C₂₂ acyl glycinate salts. Suitable glycinate salts include sodiumcocoylglycinate, potassium cocoylglycinate, sodium lauroylglycinate,potassium lauroylglycinate, sodium myristoylglycinate, potassiummyristoylglycinate, sodium palmitoylglycinate, potassiumpalmitoylglycinate, sodium stearoylglycinate, potassiumstearoylglycinate, ammonium cocoylglycinate and mixtures thereof.Cationic counter-ions to form the salt of the glycinate may be selectedfrom sodium, potassium, ammonium, alkanolammonium and mixtures of thesecations.

Suitable cationic surfactants include, but are not limited to alkyldimethylamines, alkyl amidopropylamines, alkyl imidazoline derivatives,quaternised amine ethoxylates, and quaternary ammonium compounds.

Suitable nonionic surfactants include, but are not limited to, alcohols,acids, amides or alkyl phenols reacted with alkylene oxides, especiallyethylene oxide either alone or with propylene oxide. Specific nonionicsare C₆ to C₂₂ alkyl phenols-ethylene oxide condensates, the condensationproducts of C₈ to C₁₃ aliphatic primary or secondary linear or branchedalcohols with ethylene oxide, and products made by condensation ofethylene oxide with the reaction products of propylene oxide andethylenediamine. Other nonionics include long chain tertiary amineoxides, long chain tertiary phosphine oxides and dialkyl sulphoxides,alkyl polysaccharides, amine oxides, block copolymers, castor oilethoxylates, ceto-oleyl alcohol ethoxylates, ceto-stearyl alcoholethoxylates, decyl alcohol ethoxylates, dinonyl phenol ethoxylates,dodecyl phenol ethoxylates, end-capped ethoxylates, ether aminederivatives, ethoxylated alkanolamides, ethylene glycol esters, fattyacid alkanolamides, fatty alcohol alkoxylates, lauryl alcoholethoxylates, mono-branched alcohol ethoxylates, natural alcoholethoxylates, nonyl phenol ethoxylates, octyl phenol ethoxylates, oleylamine ethoxylates, random copolymer alkoxylates, sorbitan esterethoxylates, stearic acid ethoxylates, stearyl amine ethoxylates,synthetic alcohol ethoxylates, tall oil fatty acid ethoxylates, tallowamine ethoxylates and trid tridecanol ethoxylates.

Suitable zwitterionic surfactants include, for example, alkyl amineoxides, silicone amine oxides, and combinations thereof. Specificexamples of suitable zwitterionic surfactants include, for example,4-[N,N-di(2-hydroxyethyl)-N-octadecylammonio]-butane-1-carboxylate,S—[S-3-hydroxypropyl-S-hexadecylsulfonio]-3-hydroxypentane-1-sulfate,3-[P,P-diethyl-P-3,6,9-trioxatetradexopcylphosphonio]-2-hydroxypropane-1-phosphate,3-[N,N-dipropyl-N-3-dodecoxy-2-hydroxypropylammonio]-propane-1-phosphonate,3-(N,N-dimethyl-N-hexadecylammonio)propane-1-sulfonate,3-(N,N-dimethyl-N-hexadecylammonio)-2-hydroxypropane-1-sulfonate,4-[N,N-di(2-hydroxyethyl)-N-(2-hydroxydodecyl)ammonio]-butane-1-carboxylate,3-[S-ethyl-S-(3-dodecoxy-2-hydroxypropyl)sulfonio]-propane-1-phosphate,3-[P,P-dimethyl-P-dodecylphosphonio]-propane-1-phosphonate,5-[N,N-di(3-hydroxypropyl)-N-hexadecylammonio]-2-hydroxy-pentane-1-sulfate,and combinations thereof.

Suitable amphoteric surfactants include, but are not limited to,derivatives of aliphatic quaternary ammonium, phosphonium, and sulfoniumcompounds, in which the aliphatic radicals can be straight or branchedchain, and wherein one of the aliphatic substituents contains from about8 to about 18 carbon atoms and one substituent contains an anionicgroup, e.g., carboxy, sulfonate, sulfate, phosphate, or phosphonate.Illustrative amphoterics are coco dimethyl carboxymethyl betaine,cocoamidopropyl betaine, cocobetaine, oleyl betaine, cetyl dimethylcarboxymethyl betaine, lauryl bis-(2-hydroxyethyl) carboxymethylbetaine, stearyl bis-(2-hydroxypropyl) carboxymethyl betaine, oleyldimethyl gamma-carboxypropyl betaine, laurylbis-(2-hydroxypropyl)alpha-carboxyethyl betaine, cocoamphoacetates, andcombinations thereof. The sulfobetaines may include stearyl dimethylsulfopropyl betaine, lauryl dimethyl sulfoethyl betaine, laurylbis-(2-hydroxyethyl) sulfopropyl betaine and combinations thereof.

Rheology Modifier

Optionally, one or more rheology modifiers, such as thickeners, may beadded to the anti-adherent compositions. Suitable rheology modifiers arecompatible with the anti-adherent agent. As used herein, “compatible”refers to a compound that, when mixed with the anti-adherent agent, doesnot adversely affect the anti-adherent properties of same.

A thickening system is used in the anti-adherent compositions to adjustthe viscosity and stability of the compositions. Specifically,thickening systems prevent the composition from running off of the handsor body during dispensing and use of the composition. When theanti-adherent composition is used with a wipe product, a thickerformulation can be used to prevent the composition from migrating fromthe wipe substrate.

The thickening system should be compatible with the compounds used inthe present disclosure; that is, the thickening system, when used incombination with the anti-adherent compounds, should not precipitateout, form a coacervate, or prevent a user from perceiving theconditioning benefit (or other desired benefit) to be gained from thecomposition. The thickening system may include a thickener which canprovide both the thickening effect desired from the thickening systemand a conditioning effect to the user's skin.

Thickeners may include, cellulosics, gums, acrylates, starches andvarious polymers. Suitable examples include are not limited tohydroxethyl cellulose, xanthan gum, guar gum, potato starch, and cornstarch. In some embodiments, PEG-150 stearate, PEG-150 distearate,PEG-175 diisostearate, polyglyceryl-10 behenate/eicosadioate,disteareth-100 IPDI, polyacrylamidomethylpropane sulfonic acid,butylated PVP, and combinations thereof may be suitable.

While the viscosity of the compositions will typically depend on thethickener used and the other components of the compositions, thethickeners of the compositions suitably provide for a composition havinga viscosity in the range of greater than 10 cP to about 30,000 cP ormore. In another embodiment, the thickeners provide compositions havinga viscosity of from about 100 cP to about 20,000 cP. In yet anotherembodiment, thickeners provide compositions having a viscosity of fromabout 200 cP to about 15,000 cP.

Typically, the anti-adherent compositions of the present disclosureinclude the thickening system in an amount of no more than about 20% (bytotal weight of the composition), or from about 0.01% (by total weightof the composition) to about 20% (by total weight of the composition).In another aspect the thickening system is present in the anti-adherentcomposition in an amount of from about 0.10% (by total weight of thecomposition) to about 10% (by total weight of the composition), or fromabout 0.25% (by total weight of the composition) to about 5% (by totalweight of the composition), or from about 0.5% (by total weight of thecomposition) to about 2% (by total weight of the composition).

Foaming Agents

In one embodiment, the anti-adherent compositions can be delivered as afoam. In accordance with the present disclosure, in order to make thecomposition foamable, the composition is combined with a foaming agentsuch as at least one derivatized dimethicone.

The foaming agent is capable of causing the compositions to foam whenthe compositions are combined with air using, for instance, a manualpump dispenser. Although the anti-adherent compositions may be dispensedfrom an aerosol container, an aerosol is not needed in order to causethe compositions to foam. Also of particular advantage, the compositionsare foamable without having to include fluorinated surfactants.

Various different derivatized dimethicone foaming agents may be used inthe compositions of the present disclosure. The derivatized dimethicone,for instance, may comprise a dimethicone copolyol, such as anethoxylated dimethicone. In one embodiment, the derivatized dimethiconeis linear, although branched dimethicones may be used.

The amount of foaming agent present in the foaming compositions candepend upon various factors and the desired result. In general, thefoaming agent can be present in an amount from about 0.01% to about 10%(by total weight of the composition), or from about 0.1% to about 5% (bytotal weight of the composition), or from about 0.1% to about 2% (bytotal weight of the composition).

When an anti-adherent composition is made foamable, it may be containedin an aerosol container. In an aerosol container, the composition ismaintained under pressure sufficient to cause foam formation whendispensed.

Emulsifiers

In one embodiment, the anti-adherent compositions may includehydrophobic and hydrophilic ingredients, such as a lotion or cream.Generally, these emulsions have a dispersed phase and a continuousphase, and are generally formed with the addition of a surfactant or acombination of surfactants with varying hydrophilic/lipopiliclipophilicbalances (HLB). Suitable emulsifiers include surfactants having HLBvalues from 0 to 20, or from 2 to 18. Suitable non-limiting examplesinclude Ceteareth-20, Cetearyl Glucoside, Ceteth-10, Ceteth-2,Ceteth-20, Cocamide MEA, Glyceryl Laurate, Glyceryl Stearate, PEG-100Stearate, Glyceryl Stearate, Glyceryl Stearate SE, Glycol Distearate,Glycol Stearate, Isosteareth-20, Laureth-23, Laureth-4, Lecithin, MethylGlucose Sesquistearate, Oleth-10, Oleth-2, Oleth-20, PEG-100 Stearate,PEG-20 Almond Glycerides, PEG-20 Methyl Glucose Sesquistearate, PEG-25Hydrogenated Castor Oil, PEG-30 Dipolyhydroxystearate, PEG-4 Dilaurate,PEG-40 Sorbitan Peroleate, PEG-60 Almond Glycerides, PEG-7 Olivate,PEG-7 Glyceryl Cocoate, PEG-8 Dioleate, PEG-8 Laurate, PEG-8 Oleate,PEG-80 Sorbitan Laurate, Polysorbate 20, Polysorbate 60, Polysorbate 80,Polysorbate 85, Propylene Glycol Isostearate, Sorbitan Isostearate,Sorbitan Laurate, Sorbitan Monostearate, Sorbitan Oleate, SorbitanSesquioleate, Sorbitan Stearate, Sorbitan Trioleate, Stearamide MEA,Steareth-100, Steareth-2, Steareth-20, Steareth-21. The compositions canfurther include surfactants or combinations of surfactants that createliquid crystalline networks or liposomal networks. Suitable non-limitingexamples include OLIVEM 1000 (INCI: Cetearyl Olivate (and) SorbitanOlivate (available from HallStar Company (Chicago, Ill.)); ARLACEL LC(INCI: Sorbitan Stearate (and) Sorbityl Laurate, commercially availablefrom Croda (Edison, N.J.)); CRYSTALCAST MM (INCI: Beta Sitosterol (and)Sucrose Stearate (and) Sucrose Distearate (and) Cetyl Alcohol (and)Stearyl Alcohol, commercially available from MMP Inc. (South Plainfield,N.J.)); UNIOX CRISTAL (INCI: Cetearyl Alcohol (and) Polysorbate 60 (and)Cetearyl Glucoside, commercially available from Chemyunion (Sào Paulo,Brazil)). Other suitable emulsifiers include lecithin, hydrogenatedlecithin, lysolecithin, phosphatidylcholine, phospholipids, andcombinations thereof.

Adjunct Ingredients

The anti-adherent compositions of the present disclosure mayadditionally include adjunct ingredients conventionally found inpharmaceutical compositions in an established fashion and at establishedlevels. For example, the anti-adherent compositions may compriseadditional compatible pharmaceutically active and compatible materialsfor combination therapy, such as antioxidants, anti-parasitic agents,antipruritics, antifungals, antiseptic actives, biological actives,astringents, keratolytic actives, local anaesthetics, anti-stingingagents, anti-reddening agents, skin soothing agents, externalanalgesics, film formers, skin exfoliating agents, sunscreens, andcombinations thereof.

Other suitable additives that may be included in the anti-adherentcompositions of the present disclosure include compatible colorants,deodorants, emulsifiers, anti-foaming agents (when foam is not desired),lubricants, skin conditioning agents, skin protectants and skin benefitagents (e.g., aloe vera and tocopheryl acetate), solvents, solubilizingagents, suspending agents, wetting agents, pH adjusting ingredients (asuitable pH range of the compositions can be from about 3.5 to about 8),chelators, propellants, dyes and/or pigments, and combinations thereof.

Another component that may be suitable for addition to the anti-adherentcompositions is a fragrance. Any compatible fragrance may be used.Typically, the fragrance is present in an amount from about 0% (byweight of the composition) to about 5% (by weight of the composition),and more typically from about 0.01% (by weight of the composition) toabout 3% (by weight of the composition). In one desirable embodiment,the fragrance will have a clean, fresh and/or neutral scent to create anappealing delivery vehicle for the end consumer.

Organic sunscreens that may be present in the anti-adherent compositionsinclude ethylhexyl methoxycinnamate, avobenzone, octocrylene,benzophenone-4, phenylbenzimidazole sulfonic acid, homosalate,oxybenzone, benzophenone-3, ethylhexyl salicylate, and mixtures thereof.

As previously noted, in some embodiments, antimicrobial agents can beadded to the anti-adherent compositions as optional ingredients. Forexample, suitable antimicrobials include biocides such as a short-chainalcohol, benzoalkonium chloride (“BAC”), didecyl dimethyl ammoniumchloride (“DDAC”), and zeolite (“CWT-A”). Other possible antimicrobialagents include: isothiazolone, alkyl dimethyl ammonium chloride, atriazine, 2-thiocyanomethylthio benzothiazol, methylene bis thiocyanate,acrolein, dodecylguanidine hydrochloride, a chlorophenol, a quaternaryammonium salt, gluteraldehyde, a dithiocarbamate,2-mercatobenzothiazole, para-chloro-meta-xylenol, silver,chlorohexidine, polyhexamethylene biguanide, a n-halamine, triclosan, aphospholipid, an alpha hydroxyl acid, 2,2-dibromo-3-nitrilopropionamide,2-bromo-2-nitro-1,3-propanediol, farnesol, iodine, bromine, hydrogenperoxide, chlorine dioxide, a botanical oil, a botanical extract,benzalkonium chloride, chlorine, sodium hypochlorite, or combinationsthereof. In some embodiments, the antimicrobial agent can beantibacterial. In some embodiments, the antimicrobial agent can beantiviral. In some embodiments, the antimicrobial agent can beantibacterial and antiviral.

If present, the amount of the antimicrobial agent in the anti-adherentcompositions can be in an amount between about 0.01% to about 5% (bytotal weight of the composition), or in some embodiments between about0.05% to about 3% (by total weight of the composition). In someembodiments, the antimicrobial agent can be provided to theanti-adherent composition at an effective amount such that a kill of adesired microbe reaches the IC₅₀ (inhibitory concentration 50%) for thatdesired microbe with that antimicrobial agent in the anti-adherentcomposition. In some embodiments, the antimicrobial agent can beprovided to the anti-adherent composition at less than an effectiveamount such that a kill of a desired microbe does not reach the IC₅₀ forthat desired microbe with that antimicrobial agent in the anti-adherentcomposition, in which case the anti-adherent composition would still beconsidered non-antimicrobial for purposes of this disclosure. Aspreviously noted, antimicrobial agents are merely optional ingredients.

Preservatives

The anti-adherent compositions may include various preservatives toincrease shelf life. Some suitable preservatives that may be used in thepresent disclosure include, but are not limited to phenoxyethanol,capryl glycol, glyceryl caprylate, sorbic acid, gallic acid, KATHON CG®,which is a mixture of methylchloroisothiazolinone andmethylisothiazolinone, (available from Rohm & Haas Company,Philadelphia, Pa.); DMDM hydantoin (e.g., GLYDANT, available from Lonza,Inc., Fair Lawn, N.J.); EDTA and salts thereof; iodopropynylbutylcarbamate; benzoic esters (parabens), such as methylparaben,propylparaben, butylparaben, ethylparaben, isopropylparaben,isobutylparaben, benzylparaben, sodium methylparaben, and sodiumpropylparaben; 2-bromo-2-nitropropane-1,3-diol; benzoic acid; and thelike. Other suitable preservatives include those sold by Sutton LabsInc., Chatham, N.J., such as “GERMALL 115” (imidazolidinyl urea),“GERMALL II” (diazolidinyl urea), and “GERMALL PLUS” (diazolidinyl ureaand iodopropynyl butylcarbonate).

The amount of the preservative in the anti-adherent compositions isdependent on the relative amounts of other components present within thecomposition. For example, in some embodiments, the preservative ispresent in the compositions in an amount between about 0.001% to about5% (by total weight of the composition), in some embodiments betweenabout 0.01 to about 3% (by total weight of the composition), and in someembodiments, between about 0.05% to about 1.0% (by total weight of thecomposition).

Preparation of Anti-Adherent Compositions

The anti-adherent compositions of the present disclosure may be preparedby combining ingredients at room temperature and mixing.

In one embodiment, when the anti-adherent composition is to be appliedto the skin of an individual, the composition includes the anti-adherentagent, a hydrophilic carrier and a hydrophilic thickener. Suitablehydrophilic carriers can be, for example, water, glycerin, glycerinderivatives, glycols, water-soluble emollients, and combinationsthereof. Suitable examples of glycerin derivatives could include, butare not to be limited to, PEG-7 glyceryl cocoate. Suitable glycols couldinclude, but are not to be limited to, propylene glycol, butyleneglycol, pentylene glycol, ethoxydiglycol, dipropylene glycol,propanediol, and PEG-8. Suitable examples of water-soluble emollientscould include, but are not to be limited to, PEG-6 Caprylic CapricGlycerides, Hydrolyzed Jojoba Esters, and PEG-10 Sunflower Glycerides.

Delivery Vehicles

The anti-adherent compositions of the present disclosure may be used incombination with a product. For example, the composition may beincorporated into or onto a substrate, such as a wipe substrate, anabsorbent substrate, a fabric or cloth substrate, a tissue or papertowel substrate, or the like. In one embodiment, the anti-adherentcomposition may be used in combination with a wipe substrate to form awet wipe or may be a wetting composition for use in combination with awipe which may be dispersible. In other embodiments, the anti-adherentcomposition may be incorporated into wipes such as wet wipes, handwipes, face wipes, cosmetic wipes, cloths and the like. In yet otherembodiments, the anti-adherent compositions described herein can be usedin combination with numerous personal care products, such as absorbentarticles. Absorbent articles of interest are diapers, training pants,adult incontinence products, feminine hygiene products, and the like;bath or facial tissue; and paper towels. Personal protective equipmentarticles of interest include but are not limited to masks, gowns,gloves, caps, and the like.

In one embodiment, the wet wipe may comprise a nonwoven material that iswetted with an aqueous solution termed the “wetting composition,” whichmay include or be composed entirely of the anti-adherent compositionsdisclosed herein. As used herein, the nonwoven material comprises afibrous material or substrate, where the fibrous material or substratecomprises a sheet that has a structure of individual fibers or filamentsrandomly arranged in a mat-like fashion. Nonwoven materials may be madefrom a variety of processes including, but not limited to, airlaidprocesses, wet-laid processes such as with cellulosic-based tissues ortowels, hydroentangling processes, staple fiber carding and bonding,melt blown, and solution spinning.

The fibers forming the fibrous material may be made from a variety ofmaterials including natural fibers, synthetic fibers, and combinationsthereof. The choice of fibers may depend upon, for example, the intendedend use of the finished substrate and the fiber cost. For instance,suitable fibers may include, but are not limited to, natural fibers suchas cotton, linen, jute, hemp, wool, wood pulp, etc. Similarly, suitablefibers may also include: regenerated cellulosic fibers, such as viscoserayon and cuprammonium rayon; modified cellulosic fibers, such ascellulose acetate; or synthetic fibers, such as those derived frompolypropylenes, polyethylenes, polyolefins, polyesters, polyamides,polyacrylics, etc. Regenerated cellulose fibers, as briefly discussedabove, include rayon in all its varieties as well as other fibersderived from viscose or chemically modified cellulose, includingregenerated cellulose and solvent-spun cellulose, such as Lyocell. Amongwood pulp fibers, any known papermaking fibers may be used, includingsoftwood and hardwood fibers. Fibers, for example, may be chemicallypulped or mechanically pulped, bleached or unbleached, virgin orrecycled, high yield or low yield, and the like. Chemically treatednatural cellulosic fibers may be used, such as mercerized pulps,chemically stiffened or crosslinked fibers, or sulfonated fibers.

In addition, cellulose produced by microbes and other cellulosicderivatives may be used. As used herein, the term “cellulosic” is meantto include any material having cellulose as a major constituent, and,specifically, comprising at least 50 percent by weight cellulose or acellulose derivative. Thus, the term includes cotton, typical woodpulps, non-woody cellulosic fibers, cellulose acetate, cellulosetriacetate, rayon, thermomechanical wood pulp, chemical wood pulp,debonded chemical wood pulp, milkweed, or bacterial cellulose. Blends ofone or more of any of the previously described fibers may also be used,if so desired.

The fibrous material may be formed from a single layer or multiplelayers. In the case of multiple layers, the layers are generallypositioned in a juxtaposed or surface-to-surface relationship and all ora portion of the layers may be bound to adjacent layers. The fibrousmaterial may also be formed from a plurality of separate fibrousmaterials wherein each of the separate fibrous materials may be formedfrom a different type of fiber.

Airlaid nonwoven fabrics are particularly well suited for use as wetwipes. The basis weights for airlaid nonwoven fabrics may range fromabout 20 to about 200 grams per square meter (gsm) with staple fibershaving a denier of about 0.5 to about 10 and a length of about 6 toabout 15 millimeters. Wet wipes may generally have a fiber density ofabout 0.025 g/cc to about 0.2 g/cc. Wet wipes may generally have a basisweight of about 20 gsm to about 150 gsm. More desirably the basis weightmay be from about 30 to about 90 gsm. Even more desirably the basisweight may be from about 50 gsm to about 75 gsm.

Processes for producing airlaid non-woven basesheets are described in,for example, published U.S. Pat. App. No. 2006/0008621, hereinincorporated by reference to the extent it is consistent herewith.

As a result of the present disclosure, it has been discovered that ananti-adherent composition including an anti-adherent agent can beemployed to inhibit the adherence of microbes to a surface. Thus, in oneembodiment, an anti-adherent composition can be applied to a surface(e.g., countertop, wall, table, skin, etc.). At least some of theanti-adherent composition can be allowed to remain on the surface suchthat the anti-adherent agent can inhibit microbes from attaching to thesurface, and therefore, reduce the amount of microbes that will adhereto that surface. By reducing the amount of microbes that will adhere tothat surface, the anti-adherent composition can be used to reduce thelikelihood that individuals come into contact with microbes, and therebyreduce the spreading of the microbes. This benefit could be providedwhether the anti-adherent composition was provided in the form of aliquid, gel, or foam; or incorporated into a wash, or is provided on orin a delivery vehicle such as a fibrous substrate (e.g., a wipe).

The disclosure will be more fully understood upon consideration of thefollowing non-limiting examples described in the following section ontesting.

Testing

From testing conducted and as described further below, it has beendiscovered that an anti-adherent composition including an anti-adherentagent of the present disclosure can inhibit microbes from attaching oradhering to a surface. The anti-adherent agent can be selected from thegroup consisting of: Acrylates Copolymer, Trimethylpentanediol/AdipicAcid/Glycerin crosspolymer, Trimethylpentanediol/Adipic Acid Copolymer,Ethylhexyl Stearate, Ethylhexyl Salicylate, Acrylates/C12-22Alkylmethacrylate Copolymer, Octocrylene, Ethylene Oxide/Propylene OxideBlock Copolymer, and Polyquaternium-101, and any combinations thereof.Anti-adherent compositions including the anti-adherent agents ofAcrylates Copolymer and Ethylhexyl Stearate provided an anti-adherenteffect against each of the types of microbes Gram Negative bacteria,Gram positive bacteria, DNA viruses, and RNA viruses in the testingconducted and as described further below. Anti-adherent compositionsincluding other anti-adherent agents provided an anti-adherent effectagainst one or more, but not all, of the types of microbes tested.

Attachment Against Bacteria

Anti-adherent compositions including anti-adherent agents as discussedherein were tested against bacteria using the High Throughput AttachmentTest Method. The High Throughput Attachment Test Method is discussed infurther detail below. The anti-adherent compositions including theanti-adherent agents were tested against Gram-positive Staphylococcusaureus, and Gram-negative Escherichia coli. The pH of the compositionsfor this testing between 3 to 10 pH, or about 4 to about 8 pH. Theresults of the testing is shown below in Table 1.

TABLE 1 Compounds and corresponding ratio of bacteria growth on treatedpegs to untreated pegs according to High Throughput Attachment TestMethod Ratio of Ratio of E. coli S. aureus growth on growth on treatedtreated pegs to pegs to Compound Con. untreated untreated Compound NameWt. pegs pegs # Type (Manufacturer) %* INCI Name (%) (%) 1 SyntheticDeposilk Q1 5 Polyquaternium-101 87.8 104.9 Polymer (Air Products andChemicals, Inc.) 2 Synthetic Allianz OPT 2 Acrylates/C12-22 89.7 73.4Polymer (Ashland Inc.) Alkylmethacrylate Copolymer 3 SyntheticCarbopol ® Aqua 2 Acrylates Copolymer 71.5 55.6 Polymer SF-1 (LubrizolCorporation) 4 Synthetic Lexorez ® 200 5 Trimethylpentanediol/ 92.8 99.4Polymer (Inolex) Adipic Acid/Glycerin Crosspolymer 5 Synthetic Lexorez ®TL-8 5 Trimethylpentanediol/ 82.5 96.4 Polymer (Inolex) Adipic AcidCopolymer 6 Synthetic Pluronic ® 85 5 Ethylene 113.7 55.8 Polymer (BASFOxide/Propylene Corporation) Oxide Block Copolymer 7 Cosmetic OilCetiol ® 868 100 Ethylhexyl Stearate 48.4 68.6 (Ester) (BASFCorporation) 8 Cosmetic Oil Escalol ® 587 100 Ethylhexyl Salicylate111.1 75.4 (Ester) (Ashland Inc.) 9 Cosmetic Oil Escalol ® 597 100Octocrylene 114.1 81.9 (Ester) (Ashland Inc.) *Con. Wt. % =Concentration of Compound in 5% glycerin and QS water, by total weightof solution, unless compound was tested at 100% concentration

As shown in the results of Table 1 above and based on the categorizationas described by the High Throughput Attachment Test Method (a ratio ofbacterial growth on treated pegs to untreated pegs less than 85% beinganti-adherent at a statistically significant level), the anti-adherentcompositions including the anti-adherent agents of Acrylates Copolymerand Ethylhexyl Stearate provided an anti-adherent effect against bothGram negative bacteria (E. coli) and Gram positive bacteria (S. aureus).The anti-adherent composition including the anti-adherent agent ofTrimethylpentanediol/Adipic Acid Copolymer provided an anti-adherenteffect against Gram negative bacteria (E. coli), but was neutral againstGram positive bacteria (S. aureus). Additionally, the anti-adherentcompositions including the anti-adherent agents of Acrylates/C12-22Alkylmethacrylate Copolymer, Ethylene Oxide/Propylene Oxide BlockCopolymer, Ethylhexyl Salicylate, and Octocrylene provided ananti-adherent effect against Gram positive bacteria (S. aureus), but wasneutral against Gram negative bacteria (E. coli).

Attachment Against RNA and DNA Viruses

The anti-adherent compositions that inhibit the attachment of RNA and/orDNA viruses to a surface including compounds serving as anti-adherentagents against RNA and DNA viruses were tested against RNA and DNAviruses via the High Throughput Test to Quantify the Attachment of Phageto a Surface, as discussed in detail below. Tables 2 and 3 below showthe variety of compounds that were tested as agents in a composition, aswell as the results that related to the percent reduction in viruses andthe Logarithmic Reduction compared to growth controls. As will bediscussed in further detail below in the discussion regarding the HighThroughput Test to Quantify the Attachment of Phage to a Surface, apositive logarithmic reduction in viruses equates to anti-adherentproperties (e.g., inhibits attachment), and a negative logarithmicreduction in viruses equates to adherent properties (e.g., increasesattachment).

The RNA virus that the compositions were tested against for attachmentbehaviors was MS2. Bacteriophage are commonly utilized as surrogates ofmammalian viruses in both medical and virology applications. MS2 phageis commonly utilized as a viral surrogate because of its size,morphology, environmental stability, non-human infectivity, and theability for use in high throughput assays. Additionally, MS2 is commonlyused as a surrogate to study the spread of human Norovirus (See,Tung-Thompson, et al, PLoS One, 2015, 10(8): e0134277, Dawson D J, etal, J App Micro, 2005, 98: 203-209, Jones, et al, J Hosp Infect, 1991,17:279-85). The use of MS2 phage in hand sanitizer studies makes it anideal surrogate to study the interaction of personal care products andviral attachment. It is believed that compositions including theadherent agents noted above would act in a substantially similarbehavior to other RNA viruses as they did against MS2.

The DNA virus that the compositions were tested against for attachmentbehaviors was Phi X 174. Bacteriophage are commonly utilized assurrogates of mammalian viruses in both medical and virologyapplications. Phi X 174 is commonly utilized as a viral surrogatebecause of its size, morphology, environmental stability, and non-humaninfectivity, and the ability for use in high throughput assays. Phi X174has been previously been used to study barrier efficacy, making it anideal surrogate to study attachment to a surface (See, Hamann andNelson, Am J Infect Control, 1993, 21:289-96, O'Connell, et al, ClinMicrob Infect, 2004, 10:322-6, ASTM F1671/F1671M-13, Standard TestMethod for Resistance of Materials Used in Protective Clothing toPenetration by Blood-Borne Pathogens Using Phi X174 BacteriophagePenetration as a Test System). Thus, it is well accepted by those ofordinary skill in the art that Phi X 174 serves as a surrogate for otherDNA viruses, and the compositions including the adherent agents notedabove would act in a substantially similar behavior to other DNA virusesas they did against Phi X 174.

As can be seen from Table 2, several of the compounds exhibited positivelogarithmic reductions in testing against RNA viruses at statisticallysignificant levels, and thus, can help to inhibit adherence of an RNAvirus to a surface. Additionally, as can be seen from Table 3 below,several of the compounds exhibited positive logarithmic reductions intesting against DNA viruses at statistically significant levels, andthus, can help to inhibit adherence of a DNA virus to a surface. Theanti-adherent compositions including the anti-adherent agents ofAcrylates Copolymer, Trimethylpentanediol/Adipic Acid/GlycerinCrosspolymer, Trimethylpentanediol/Adipic Acid Copolymer, EthylhexylStearate, and Ethylhexyl Salicylate provided an anti-adherent effectagainst both RNA viruses and DNA viruses. The anti-adherent compositionsincluding the anti-adherent agent of Polyquaternium-101 provided ananti-adherent effect against RNA viruses, but was neutral against DNAviruses. The anti-adherent compositions including the anti-adherentagents of Acrylates/C12-22 Alkylmethacrylate Copolymer, EthyleneOxide/Propylene Oxide Block Copolymer, and Octocrylene provided ananti-adherent effect against DNA viruses, but were neutral against RNAviruses.

TABLE 2 Compounds and Percent Reductions and Logarithmic Reductions ofRNA viruses according to High Throughput Test to Quantify the Attachmentof Phage to a Surface MS2 Log R MS2 (PFU/mL) Compound Con. Percentcompared Statistical Compound Name Wt. Reduct. to growth T-Test Signif.# Type (Manufacturer) %* INCI Name (%) controls Value e(p < 0.05) 1Synthetic Deposilk Q1 5 Polyquaternium-101 74.73 0.60 0 S Polymer (AirProducts and Chemicals, Inc.) 2 Synthetic Allianz OPT 2 Acrylates/C12-227.04 0.03 0.44 NS Polymer (Ashland Inc.) Alkylmethacrylate Copolymer 3Synthetic Carbopol ® Aqua 2 Acrylates Copolymer 66.48 0.47 0.03 SPolymer SF-1 (Lubrizol Corporation) 4 Synthetic Lexorez ® 200 5Trimethylpentanediol/ 70.06 0.52 0.04 S Polymer (Inolex) AdipicAcid/Glycerin Crosspolymer 5 Synthetic Lexorez ® TL-8 5Trimethylpentanediol/ 67.65 0.49 0.01 S Polymer (Inolex) Adipic AcidCopolymer 6 Synthetic Pluronic ® 85 5 Ethylene 37.28 0.20 0.12 NSPolymer (BASF Oxide/Propylene Corporation) Oxide Block Copolymer 7Cosmetic Oil Cetiol ® 868 100 Ethylhexyl Stearate 87.46 0.90 0 S (Ester)(BASF Corporation) 8 Cosmetic Oil Escalol ® 587 100 EthylhexylSalicylate 85.40 0.84 0 S (Ester) (Ashland Inc.) 9 Cosmetic OilEscalol ® 597 100 Octocrylene −30.27 −0.11 0.38 NS (Ester) (AshlandInc.) *Con. Wt. % = Concentration of Compound in 5% glycerin and QSwater, by total weight of solution, unless compound was tested at 100%concentration

TABLE 3 Compounds and Percent Reductions and Logarithmic Reductions ofDNA viruses according to High Throughput Test to Quantify the Attachmentof Phage to a Surface Phi X 174 Phi X Log. R 174 (PFU/mL) Compound Con.Percent compared Statistical Compound Name Wt. Reduct. to growth T-TestSignif. # Type (Manufacturer) %* INCI Name (%) controls Value e(p <0.05) 1 Synthetic Deposilk Q1 5 Polyquaternium-101 12.97 0.06 0.31 NSPolymer (Air Products and Chemicals, Inc.) 2 Synthetic Allianz OPT 2Acrylates/C12-22 82.21 0.75 0 S Polymer (Ashland Inc.) AlkylmethacrylateCopolymer 3 Synthetic Carbopol ® Aqua 2 Acrylates Copolymer 81.69 0.74 0S Polymer SF-1 (Lubrizol Corporation) 4 Synthetic Lexorez ® 200 5Trimethylpentanediol/ 94.70 1.28 0 S Polymer (Inolex) AdipicAcid/Glycerin Crosspolymer 5 Synthetic Lexorez ® TL-8 5Trimethylpentanediol/ 87.85 0.92 0 S Polymer (Inolex) Adipic AcidCopolymer 6 Synthetic Pluronic ® 85 5 Ethylene 93.91 1.22 0 S Polymer(BASF Oxide/Propylene Corporation) Oxide Block Copolymer 7 Cosmetic OilCetiol ® 868 100 Ethylhexyl Stearate 98.58 1.85 0 S (Ester) (BASFCorporation) 8 Cosmetic Oil Escalol ® 587 100 Ethylhexyl Salicylate91.45 1.07 0 S (Ester) (Ashland Inc.) 9 Cosmetic Oil Escalol ® 597 100Octocrylene 93.44 1.18 0 S (Ester) (Ashland Inc.) *Con. Wt. % =Concentration of Compound in 5% glycerin and QS water, by total weightof solution, unless compound was tested at 100% concentration

Test Methods High Throughput Attachment Test Method

This test method specifies the operational parameters required to growand or prevent the formation of bacterial attachment using a highthroughput screening assay. The assay device consists of a plastic lidwith ninety-six (96) pegs and a corresponding receiver plate withninety-six (96) individual wells that have a maximum 200 μL workingvolume. Biofilm is established on the pegs under static batch conditions(i.e., no flow of nutrients into or out of an individual well).

-   -   1. Terminology        -   1.2 Definitions of Terms Specific to This Standard:        -   1.2.2 peg, n—biofilm sample surface (base: 5.0 mm, height:            13.1 mm).        -   1.2.3 peg lid, n—an 86×128 mm plastic surface consisting of            ninety-six (96) identical pegs.        -   1.2.4 plate, n—an 86×128 mm standard plate consisting of            ninety-six (96) identical wells.        -   1.2.5 well, n—small reservoir with a 50 to 200 μL working            volume capacity.    -   2. Acronyms        -   2.2 ATCC: American Type Culture Collection        -   2.3 CFU: colony forming unit        -   2.4 rpm: revolutions per minute        -   2.5 SC: sterility control        -   2.6 TSA: tryptic soy agar        -   2.7 TSB: tryptic soy broth        -   2.8 GC: growth control    -   3. Apparatus        -   3.2 Inoculating loop—nichrome wire or disposable plastic.        -   3.3 Petri dish—large labelled (100×150×15 mm, plastic,            sterile) for plating.        -   3.4 Microcentrifuge tubes—sterile, any with a 1.5 mL volume            capacity.        -   3.5 96-well microtiter plate—sterile, 86×128 mm standard            plate consisting of ninety-six (96) identical flat bottom            wells with a 200 μL working volume        -   3.6 Vortex—any vortex that will ensure proper agitation and            mixing of microfuge tubes.        -   3.7 Pipette—continuously adjustable pipette with volume            capability of 1 mL.        -   3.8 Micropipette—continuously adjustable pipette with            working volume of 10 μL-200 μL.        -   3.9 Sterile pipette tips—200 uL and 1000 uL volumes.        -   3.10 Sterile reagent reservoir—50 mL polystyrene.        -   3.11 Sterilizer—any steam sterilizer capable of producing            the conditions of sterilization.        -   3.12 Colony counter—any one of several types may be used. A            hand tally for the recording of the bacterial count is            recommended if manual counting is done.        -   3.13 Environmental incubator—capable of maintaining a            temperature of 35±2° C. and relative humidity between 35 and            85%.        -   3.14 Reactor components—the MBEC Assay device available from            Innovotech, Edmonton, AB, Canada.        -   3.15 Sterile conical tubes—50 mL, used to prepare initial            inoculum.        -   3.16 Appropriate glassware—as required to make media and            agar plates.        -   3.17 Erlenmeyer flask—used for growing broth inoculum.        -   3.18 Positive Displacement pipettes capable of pipetting 200            μL.        -   3.19 Sterile pipette tips appropriate for Positive            Displacement pipettes.    -   4. Reagents and Materials        -   4.2 Purity of water—all references to water as diluent or            reagent shall mean distilled water or water of equal purity.        -   4.3 Culture media:        -   4.4 Bacterial growth broth—Tryptic soy broth (TSB) prepared            according to manufacturer's directions.        -   4.5 Bacterial plating medium—Tryptic soy agar (TSA) prepared            according to manufacturer's directions.        -   4.6 Phosphate Buffered Saline (PBS)—        -   4.7 Rinse Solution: Sterile PBS and TWEEN 80 (Sigma-Aldrich,            St. Louis, Mo.) 1% w/v.    -   5. Microorganisms:        -   5.1 E. coli ATCC 11229 and S. aureus ATCC 6538    -   6. TEST METHOD overview: The experimental process for the        High-Throughput Anti-Adherence Test Method. This standard        protocol may be broken into a series of small steps, each of        which is detailed in the sections below.        -   6.1 Culture Preparation        -   6.1.1 E. coli ATCC 11229 and S. aureus ATCC 6538 are the            organisms used in this test.        -   6.1.2 Using a cryogenic stock (at −70° C.), streak out a            subculture of the above listed microorganisms on organism's            specific agar (TSA).        -   6.1.3 Incubate at 35±2° C. for the period of time of 22±2            hours.        -   6.1.4 Aseptically remove isolated colony from streak plate            and inoculate 20 mL of sterile TSB.        -   6.1.5 Incubate flask at 35±2° C. and 175±10 rpm for 16 to 18            hours (E. coli and S. aureus). Viable bacterial density            should be 10⁹ CFU/mL and should be checked by serial            dilution and plating.        -   6.1.6 Pipette 10 mL from the incubation flask of E. coli            and S. aureus into a 50 mL conical tube and spin down at 5            minutes at 4,000×g. Then remove supernatant and Resuspend in            10 mL sterile PBS. Approximate cell density should be            10⁷-10⁹ CFU/mL. Vortex the sample for approximately 30            seconds to achieve a homogeneous distribution of cells.        -   6.1.7 Perform 10-fold serial dilutions of the inoculum in            triplicate.        -   6.1.8 Plate appropriate dilutions on appropriately labelled            TSA plates. Incubate the plates at 35±2° C. for 22±2 hours            depending on the isolates growth rate and enumerate.        -   6.2 Preparation of the Challenge plates:        -   6.2.1 Preparation of compounds and coating compounds onto            MBEC plate lid        -   6.2.1.1.1 Using a positive displacement pipette aseptically            add 200 μL of compounds and control to be tested to a            sterile 96-well microplate according to the plate layout of            Table 4 below.

TABLE 4 Sample layout of 96-well MBEC plate. 1 2 3 4 5 6 7 8 9 10 11 12E. coli A AC T1 T2 T3 T4 T5 T6 T7 T8 NT-GC T1-SC E. coli B AC T1 T2 T3T4 T5 T6 T7 T8 NT-GC T2-SC E. coli C AC T1 T2 T3 T4 T5 T6 T7 T8 NT-GCT3-SC E. coli D AC T1 T2 T3 T4 T5 T6 T7 T8 NT-GC T4-SC S. aureus E AC T1T2 T3 T4 T5 T6 T7 T8 NT-GC T5-SC S. aureus F AC T1 T2 T3 T4 T5 T6 T7 T8NT-GC T6-SC S. aureus G AC T1 T2 T3 T4 T5 T6 T7 T8 NT-GC T7-SC S. aureusH AC T1 T2 T3 T4 T5 T6 T7 T8 NT-GC T8-SC AC = Attachment Control SC =Sterility Control NT-GC = No Treatment Growth Control T1-T8 = Test Codes

-   -   -   6.2.1.1.2 Add 200 μL of each code to the appropriate well            for sterility controls.        -   6.2.1.1.3 Place the MBEC plate lid, peg side down into the            96-well microplate containing the test compound solutions.        -   6.2.1.1.4 Allow the plate to sit at room temperature (25±3°            C.) for 2 hours.        -   6.2.1.1.5 Remove the MBEC plate lid and allow the lid to dry            at room temperature (25±3° C.) overnight in a laminar flow            hood.

    -   7.1 Bacterial Adherence Challenge:        -   7.1.1 Add 100 μL of diluted bacteria to the appropriate            wells in a sterile 96-well microplate as indicated in the            plate layout in Table 4.        -   7.1.2 Add 200 μL of sterile PBS to the sterility controls.        -   7.1.3 The MBEC containing dried compounds is then inserted            into the bacterial inoculated 96 well flat bottom microplate            from section 9.3.1        -   7.1.4 Incubate stationary at room temperature (25±3° C.) for            15 minutes.        -   7.1.5 Remove the MBEC lid and place into a 96-well            microplate containing 200 μL PBS+1% w/v TWEEN 80. Incubate            stationary at room temperature (25±3° C.) for 15 seconds.        -   7.1.6 Repeat step 7.1.5 for two additional washes for a            total of 3 washes.

    -   7.2 Method to Determine Number of Attached Bacteria        -   7.2.1 Transfer the washed MBEC plate lid to a 96-well plate            containing 200 μL ALAMARBLUE reagent (prepared according to            manufacturer's directions, Life Technologies, Carlsbad,            Calif.) in each well to be tested.        -   7.2.2 The final plate is transferred to a SPECTRAMAX GEMINI            EM microplate reader (Molecular Devices, Inc. Sunnyvale,            Calif. USA) for a 20 hour kinetic, bottom read with an            excitation of 560 nm and emission of 590 nm. The rate of            fluorescence development (relative fluorescence units            (RFU)/minute) is determined for each well.        -   7.2.3 From these data, the ratio of bacterial growth on the            test codes pegs to the bacterial growth on the nontreated            growth control pegs was calculated.            -   If the ratio of bacterial growth on the test code pegs                to the bacterial growth on the nontreated growth control                pegs is less than 85%, the agent is deemed to be                anti-adherent;            -   If the ratio of bacterial growth on the test code pegs                to the bacterial growth on the nontreated growth control                pegs is between 85%-115%, the agent is deemed to be                neutral (neither adherent nor anti-adherent); and            -   If the ratio of bacterial growth on the test code pegs                to the bacterial growth on the nontreated growth control                pegs is greater than 115%, the agent is deemed to be                adherent.

High Throughput Test to Quantify the Attachment of Phage to a Surface

1.0 Test Methods:

Growth and purification of phage is outlined in the following steps.

-   -   1.1 Subculture: (these steps ensured that the organism are less        than 5 generations removed from the original clinical isolate):        -   1.1.1 Using a cryogenic stock (at −70° C.), a first            sub-culture of the bacterial organisms listed above is            streaked out on appropriate media.        -   1.1.2 The plate is incubated at 36±2° C. for 24 hours and            store the plate is wrapped in parafilm at 4° C.        -   1.1.3 From the first sub-culture, a second sub-culture is            streaked out on appropriate media. It is incubated at            36±2° C. for 24 hours. The second sub-culture is used within            24 hours starting from the time it is first removed from            incubation.        -   1.1.4 Organism(s) from the second sub-culture are inoculated            into 30-200 mL OSB and incubated at 36±2° C. on a rotary            shaker (at approximately 150 rpm) for 16-18 hours. This is            to achieve an inoculum density of approximately 10⁹ CFU/ml.    -   1.2 Prepare Top Agar:        -   1.2.1 Top Agar is prepared by preparing 200 mL of OSB            according to manufacturer's directions and adding 0.7% agar.            After sterilization, the sterilized mix is stored in a water            bath set at 49° C.        -   1.2.2 The top agar solution is aliquoted by moving 4 mL into            sterile tubes. The tubes are kept at 49 C until needed for            use.    -   1.3 Preparation of Bacterial Host:        -   1.3.1 40 mL of broth culture is moved to a centrifuge tube.        -   1.3.2 The overnight broth culture is centrifuged at 4000×g            for 5 minutes.        -   1.3.3 The supernatant is decanted and the cells were            re-suspended in the same volume (40 mL for example) of BPB.        -   1.3.4 Steps 4.2.2 to 4.2.3 are repeated one more time.    -   1.4 Propagation of the Phage:        -   1.4.1 The OSA plates to be used are warmed to room            temperature.        -   1.4.2 The top agar tubes are inoculated with 200 μL of            concentrated phage stock from either an ATCC or a previously            stored concentrated stock. For frozen stock 500 μL of TSB            warmed to 49° C. is added before adding to the Top Agar.        -   1.4.3 100 μL of the washed broth culture is added and            swirled gently to mix.        -   1.4.4 Each inoculated top agar tube is poured onto one            prepared OSA plate. The plate is tilted to ensure that the            top agar was spread across the entire surface.        -   1.4.5 The top agar is allowed to solidify, was inverted and            placed in an incubator at 37° C. for overnight growth.        -   1.4.6 Following overnight growth the plates should show            complete clearing.        -   1.4.7 The SM Buffer solution is warmed to 49° C.        -   1.4.8 2 mL of warmed SM Buffer is added to each plate and            the top agar is scraped using sterile white Teflon            policeman. A pipette is used to transfer all the SM buffer            and top agar to a sterile tube. This is done for every            plate.        -   1.4.9 The collected top agar tubes are vortexed for 10-15            seconds.        -   1.4.10 The vortexed tubes are centrifuged at 1000×g for 25            minutes.        -   1.4.11 From each centrifuged tube the supernatants are            pooled in one new sterile tube.        -   1.4.12 A sterile 0.20 filter is prepared by flushing 2-3 mL            of 3% w/v cold (4 C) beef extract through the filter and            discarded.        -   1.4.13 The prepared filter is used to filter the pooled            recovered top agar into a fresh sterile tube.        -   1.4.14 The collected filtrate is the purified phage. Plaque            Forming Units (PFU) are checked by serially diluting and            spot plating using the method described in section 4.5.    -   1.5 Phage (MS2 and PhiX 174) Enumeration:        -   1.5.1 Phage is prepared for use from the stock by diluting            1:1 in BPB.        -   1.5.2 Spot Plate Method:            -   1.5.2.1 A cell dilution of ˜10⁶ CFU/mL of E. coli (E.                coli K12 is used for MS2 phage and E. coli C is used for                PhiX 174) is prepared from the prepared washed broth                culture by diluting in sterile BPB.            -   1.5.2.2 An inoculum check is performed on the bacterial                dilution in triplicate.            -   1.5.2.3 In a 96 well plate, columns 1-12 are filled with                180 μL of the 10⁶ CFU/ml E. coli suspension in BPB            -   1.5.2.4 20 μL of the samples to be diluted is added in                column 1.            -   1.5.2.5 10-fold (10× Dilution) in BPB is performed from                10¹-10¹² by moving 20 μL from column 1 to column 2 and                mixing. This is repeated, moving down the columns until                column 12.            -   1.5.2.6 20 μL (or 10 if agar permits) is spot plated on                a large labelled OSA plate (spot plate every second                column to avoid cross merging of spot plated phages.            -   1.5.2.7 Plates are inverted & incubated for 24 h at 37°                C.            -   1.5.2.8 After 24 h the number of PFU is counted.    -   1.6 Preparation of the Challenge Plates:

TABLE 5 The challenge will be tested using the specified contact time(Total of 6 challenge plates). 1 2 3 4 5 6 7 8 9 10 11 12 A A B C D E FSC-A GC GC B A B C D E F SC-B GC GC C A B C D E F SC-C GC GC D A B C D EF SC-D GC GC E A B C D E F SC-E GC GC F A B C D E F SC-F GC GC G A B C DE F GC GC H A B C D E F GC GC SC = sterility control wells GC = growthcontrol wells

-   -   -   1.6.1 Preparation of compounds and coating compounds onto            MBEC plate lid        -   1.6.2 Using a positive displacement pipette aseptically add            200 μL of compounds to be tested to a sterile 96-well            microplate according to the plate layout described below.        -   1.6.3 Add 200 μL of each code to the appropriate well for            sterility controls.        -   1.6.4 Place the MBEC plate lid, peg side down into the            96-well microplate containing the test compound solutions.        -   1.6.5 Allow the plate to sit at room temperature (25±3° C.)            for 2 hrs.        -   1.6.6 Remove the MBEC plate lid and allow the lid to dry at            room temperature (25±3° C.) overnight in a laminar flow hood            by spacing the MBEC plate lid from the MBEC plate trough            with two 10 μL disposable loops.

    -   1.7 Phage Attachment to MBEC Lids:        -   1.7.1 Using the phage prepared in 1:1 BPB from stock 100 μL            is added to the wells indicated by the plate layout of the            sterile 96 well plate.        -   1.7.2 The sterile MBEC lid is placed into the wells.        -   1.7.3 The plate is allowed to incubate for 1 hour at room            temperature without shaking.        -   1.7.4 Rinse plates, 3 plates per MBEC lid, by adding 200 μL            of PBS to wells indicated by the plate layout of a sterile            96 well plate.

    -   1.8 Phage Recovery:        -   1.8.1 Using flamed pliers the pegs are removed from the MBEC            lid and placed in a tube containing 5 mL BPB.        -   1.8.2 Vortex for 1 minute.        -   1.8.3 Perform a serial dilution on the recovery solution.        -   1.8.4 Enumerate the PFU by using one of the methods            indicated previously.

    -   1.9 LOG₁₀ Reduction:        -   1.9.1 In a 96 well plate, columns 1-12 are filled with 180            μL of the 10E6 CFU/ml of the appropriate E. coli suspension            in BPB        -   1.9.2 20 μL of the samples to be diluted is added in column            1.        -   1.9.3 10-fold (10× Dilution) in BPB is performed from            10E1-10e12 by moving 20 μL from column 1 to column 2 and            mixing. This is repeated, moving down the columns until            column 12.        -   1.9.4 20 μL (or 10 if agar permits) is spot plated on a            large labelled OSA plate (spot plate every second column to            avoid cross merging of spot plated phages.        -   1.9.5 Plates are inverted & incubated for 24 h at 37° C.        -   1.9.6 After 24 h the number of PFU is counted.        -   1.9.7 Cell Enumeration:            -   1.9.7.1 Count the appropriate number of colonies                according to the plating method used.            -   1.9.7.2 Calculate the arithmetic mean of the colonies                counted on the plates.

    -   The log density for one peg is calculated as follows:

LOG₁₀ (PFU/peg)=LOG₁₀[(X/B) (D)] where:

-   -   X=mean PFU,    -   B=volume plated (0.02 mL)    -   and D=dilution.    -   Calculate the overall attached bacteria accumulation by        calculating the mean of the log densities calculated.    -   Calculate the LOG₁₀ reduction for each dilution as follows: LOG        10 Reduction=Mean LOG₁₀ Growth Control−Mean LOG₁₀ Test.    -   Calculate the Percent Reduction by calculating (Log₁₀(PFU/Peg)        of the growth control pegs−Log₁₀(PFU/Peg) of the treated        pegs)/Log₁₀(PFU/Peg) of the growth control pegs)×100    -   1.10 Accept or Reject Criteria        -   1.10.1 Growth controls for the phage are between 4 and 6 Log            10        -   1.10.2 Sterility controls do not show any growth.

Embodiments

-   Embodiment 1: A method of inhibiting microbes from attaching to a    surface, the method comprising: providing an anti-adherent    composition, the anti-adherent composition comprising: an    anti-adherent agent configured to inhibit microbes from attaching to    the surface, the anti-adherent agent selected from the group    consisting of: Acrylates Copolymer, Trimethylpentanediol/Adipic    Acid/Glycerin crosspolymer, Trimethylpentanediol/Adipic Acid    Copolymer, Ethylhexyl Stearate, Ethylhexyl Salicylate,    Acrylates/C12-22 Alkylmethacrylate Copolymer, Octocrylene, Ethylene    Oxide/Propylene Oxide Block Copolymer, and Polyquaternium-101, and    any combinations thereof; applying the composition to the surface;    and allowing at least some of the composition to remain on the    surface such that the anti-adherent agent inhibits microbes from    attaching to the surface.-   Embodiment 2: The method of embodiment 1, wherein the composition    further comprises a humectant.-   Embodiment 3: The method of embodiment 2, wherein the humectant is    selected from the group consisting of: glycerin, a glycerin    derivative, and combinations thereof.-   Embodiment 4: The method of any one of the preceding embodiments,    wherein the composition further comprises an ingredient selected    from the group consisting of an emollient, a surfactant, an    antimicrobial agent, and any combination thereof.-   Embodiment 5: The method of any one of the preceding embodiments,    wherein the composition is non-antimicrobial.-   Embodiment 6: The method of any one of the preceding embodiments,    wherein the microbes comprise Gram negative bacteria, and the    anti-adherent agent is selected from the group consisting of:    Acrylates Copolymer, Trimethylpentanediol/Adipic Acid Copolymer, and    Ethylhexyl Stearate.-   Embodiment 7: The method of any one of embodiments 1-5, wherein the    microbes comprise Gram positive bacteria, and the anti-adherent    agent is selected from the group consisting of: Acrylates Copolymer,    Ethylhexyl Stearate, Ethylhexyl Salicylate, Acrylates/C12-22    Alkylmethacrylate Copolymer, Octocrylene, and Ethylene    Oxide/Propylene Oxide Block Copolymer.-   Embodiment 8: The method of any one of embodiments 1-5, wherein the    microbes comprise a DNA virus, and the anti-adherent agent is    selected from the group consisting of: Acrylates Copolymer,    Trimethylpentanediol/Adipic Acid/Glycerin crosspolymer,    Trimethylpentanediol/Adipic Acid Copolymer, Ethylhexyl Stearate,    Ethylhexyl Salicylate, Acrylates/C12-22 Alkylmethacrylate Copolymer,    Octocrylene, and Ethylene Oxide/Propylene Oxide Block Copolymer.-   Embodiment 9: The method of any one of embodiments 1-5, wherein the    microbes comprise an RNA virus, and the anti-adherent agent is    selected from the group consisting of: Acrylates Copolymer,    Trimethylpentanediol/Adipic Acid/Glycerin crosspolymer,    Trimethylpentanediol/Adipic Acid Copolymer, Ethylhexyl Stearate,    Ethylhexyl Salicylate, and Polyquaternium-101.-   Embodiment 10: An anti-adherent composition for preventing microbes    from attaching to a surface, the anti-adherent composition    comprising: an anti-adherent agent selected from the group    consisting of: Trimethylpentanediol/Adipic Acid/Glycerin    crosspolymer, Trimethylpentanediol/Adipic Acid Copolymer, Ethylhexyl    Stearate, and Acrylates/C12-22 Alkylmethacrylate Copolymer, and any    combinations thereof; and a humectant.-   Embodiment 11: The anti-adherent composition of embodiment 10,    wherein the humectant is selected from the group consisting of:    glycerin, glycerin derivatives, hyaluronic acid derivatives, betaine    derivatives amino acids, amino acid derivatives, glycosaminoglycans,    glycols, polyols, sugars, sugar alcohols, hydrogenated starch    hydrolysates, hydroxy acids, hydroxy acid derivatives, salts of PCA,    and any combination thereof.-   Embodiment 12: The anti-adherent composition of embodiment 10,    wherein the humectant is selected from the group consisting of:    honey, sorbitol, hyaluronic acid, sodium hyaluronate, betaine,    lactic acid, citric acid, sodium citrate, glycolic acid, sodium    glycolate, sodium lactate, urea, propylene glycol, butylene glycol,    pentylene glycol, ethoxydiglycol, methyl gluceth-10, methyl    gluceth-20, PEG-2, PEG-3, PEG-4, PEG-5, PEG-6, PEG-7, PEG-8, PEG-9,    PEG-10, xylitol, maltitol, and any combination thereof.-   Embodiment 13: The anti-adherent composition of embodiment 10,    wherein the humectant is selected from the group consisting of:    glycerin, a glycerin derivative, and combinations thereof.-   Embodiment 14: The anti-adherent composition of any one of    embodiments 10-13, wherein the composition further comprises an    ingredient selected from the group consisting of an emollient, a    surfactant, an antimicrobial agent, and any combination thereof.-   Embodiment 15: The anti-adherent composition of any one of    embodiments 10-14, wherein the composition is non-antimicrobial.-   Embodiment 16: The anti-adherent composition of any one of    embodiments 10-15, wherein the anti-adherent agent is present in the    amount of about 0.01% to about 20.0% by weight of the composition,    and wherein the humectant is present in the amount of about 0.01% to    about 20.0% by weight of the composition.-   Embodiment 17: An anti-adherent composition for preventing microbes    from attaching to a surface, the anti-adherent composition    comprising: an anti-adherent agent selected from the group    consisting of: Acrylates Copolymer, Trimethylpentanediol/Adipic    Acid/Glycerin Crosspolymer, Trimethylpentanediol/Adipic Acid    Copolymer, Ethylhexyl Stearate, Ethylhexyl Salicylate,    Acrylates/C12-22 Alkylmethacrylate Copolymer, and    Polyquaternium-101, and any combinations thereof; and a humectant;    wherein the anti-adherent composition is non-antimicrobial.-   Embodiment 18: The anti-adherent composition of embodiment 17,    wherein the humectant is selected from the group consisting of:    glycerin, a glycerin derivative, and combinations thereof.-   Embodiment 19: The anti-adherent agent composition of embodiment 17    or 18, wherein the anti-adherent agent is present in the amount of    about 0.01% to about 20.0% by weight of the composition, and wherein    the humectant is present in the amount of about 0.01% to about 20.0%    by weight of the composition.-   Embodiment 20: A wipe for inhibiting the attachment of microbes to a    surface, the wipe comprising: a nonwoven substrate; and the    anti-adherent composition according to any one of embodiments 10-19.

When introducing elements of the present disclosure, the articles “a”,“an”, “the” and “said” are intended to mean that there are one or moreof the elements. The terms “comprising”, “including” and “having” areintended to be inclusive and mean that there may be additional elementsother than the listed elements. Many modifications and variations of thepresent disclosure can be made without departing from the spirit andscope thereof. Therefore, the exemplary embodiments described aboveshould not be used to limit the scope of the disclosure.

1.-9. (canceled)
 10. An anti-adherent composition for preventingmicrobes from attaching to a surface, the anti-adherent compositioncomprising: an anti-adherent agent comprising at least one of:Trimethylpentanediol/Adipic Acid/Glycerin crosspolymer,Trimethylpentanediol/Adipic Acid Copolymer, Ethylhexyl Stearate, andAcrylates/C12-22 Alkylmethacrylate Copolymer, and any combinationsthereof; and a humectant.
 11. The anti-adherent composition of claim 10,wherein the humectant is selected from the group consisting of:glycerin, glycerin derivatives, hyaluronic acid derivatives, betainederivatives amino acids, amino acid derivatives, glycosaminoglycans,glycols, polyols, sugars, sugar alcohols, hydrogenated starchhydrolysates, hydroxy acids, hydroxy acid derivatives, salts of PCA, andany combination thereof.
 12. The anti-adherent composition of claim 10,wherein the humectant is selected from the group consisting of: honey,sorbitol, hyaluronic acid, sodium hyaluronate, betaine, lactic acid,citric acid, sodium citrate, glycolic acid, sodium glycolate, sodiumlactate, urea, propylene glycol, butylene glycol, pentylene glycol,ethoxydiglycol, methyl gluceth-10, methyl gluceth-20, PEG-2, PEG-3,PEG-4, PEG-5, PEG-6, PEG-7, PEG-8, PEG-9, PEG-10, xylitol, maltitol, andany combination thereof.
 13. The anti-adherent composition of claim 10,wherein the humectant is selected from the group consisting of:glycerin, a glycerin derivative, and combinations thereof.
 14. Theanti-adherent composition of claim 10, wherein the composition furthercomprises an ingredient selected from the group consisting of anemollient, a surfactant, an antimicrobial agent, and any combinationthereof.
 15. The anti-adherent composition of claim 10, wherein thecomposition is non-antimicrobial.
 16. The anti-adherent composition ofclaim 10, wherein the anti-adherent agent is present in the amount ofabout 0.01% to about 20.0% by weight of the composition, and wherein thehumectant is present in the amount of about 0.01% to about 20.0% byweight of the composition.
 17. An anti-adherent composition forpreventing microbes from attaching to a surface, the anti-adherentcomposition comprising: an anti-adherent agent comprising at least oneof: Trimethylpentanediol/Adipic Acid/Glycerin Crosspolymer,Trimethylpentanediol/Adipic Acid Copolymer, Ethylhexyl Stearate, andAcrylates/C12-22 Alkylmethacrylate Copolymer and any combinationsthereof; and a humectant; wherein the anti-adherent composition isnon-antimicrobial.
 18. The anti-adherent composition of claim 17,wherein the humectant is selected from the group consisting of:glycerin, a glycerin derivative, and combinations thereof.
 19. Theanti-adherent agent composition of claim 17, wherein the anti-adherentagent is present in the amount of about 0.01% to about 20.0% by weightof the composition, and wherein the humectant is present in the amountof about 0.01% to about 20.0% by weight of the composition.
 20. A wipefor inhibiting the attachment of microbes to a surface, the wipecomprising: a nonwoven substrate; and the anti-adherent compositionaccording to claim
 10. 21. The anti-adherent composition of claim 10,wherein the anti-adherent agent is present in an amount of at leastabout 0.10% by weight of the composition.
 22. The anti-adherentcomposition of claim 10, wherein the anti-adherent agent is present inan amount from about 0.10% to about 20% by weight of the composition.23. The anti-adherent composition of claim 10, wherein the microbescomprise Gram negative bacteria, and the anti-adherent agent comprisesat least one of: Trimethylpentanediol/Adipic Acid Copolymer andEthylhexyl Stearate.
 24. The anti-adherent composition of claim 10,wherein the microbes comprise Gram positive bacteria, and theanti-adherent agent comprises at least one of: Ethylhexyl Stearate,Acrylates/C12-22 Alkylmethacrylate Copolymer, and any combinationsthereof.
 25. The anti-adherent composition of claim 10, wherein themicrobes comprise a DNA virus, and the anti-adherent agent comprises atleast one of: Trimethylpentanediol/Adipic Acid/Glycerin crosspolymer,Trimethylpentanediol/Adipic Acid Copolymer, Ethylhexyl Stearate,Acrylates/C12-22 Alkylmethacrylate Copolymer, and any combinationsthereof.
 26. The anti-adherent composition of claim 10, wherein themicrobes comprise an RNA virus, and the anti-adherent agent comprises atleast one of: Trimethylpentanediol/Adipic Acid/Glycerin crosspolymer,Trimethylpentanediol/Adipic Acid Copolymer, Ethylhexyl Stearate, and anycombinations thereof.